CYP19A1 and cancer: These estimates are similar or worse in cancer patients or survivors; in one study of 413 women about to begin aromatase inhibitor (AI) therapy for breast cancer, only 13% had normal vitamin D levels before they started therapy (Singh, Cuzick, Mesher, Richmond, & Howell, 2012).